Previous 10 | Next 10 |
Cerecor (CERC) announces that it has entered into an exclusive license agreement with Sanford Burnham Prebys for the worldwide development and commercialization of an immune checkpoint program. Under the terms of the agreement, Sanford Burnham Prebys will receive an u...
ROCKVILLE, Md., June 23, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for immunology, immuno-oncology and rare genetic disorders, today announced that it has entered into...
Cerecor shares rise ([[CERC]] +13.8%) after announcing that it has entered into a debt financing agreement led by Horizon Technology Finance to provide up to $35M in term loans.The company said that the financing provides flexibility and extends runway through multiple clinical catalysts...
An initial tranche of $20 million drawn at the loan closing Funds ongoing clinical development of key investigational product candidates Financing provides flexibility and extends runway through multiple clinical catalysts expected in 2021 ROCKVILLE, Md. and ...
Gainers: Reata Pharmaceuticals (RETA) +20%, LifeMD (LFMD) +13%, Eloxx Pharmaceuticals (ELOX) +10%, Cerecor (CERC) +10%, Biofrontera (BFRA) +7%.Losers: Onconova Therapeutics (ONTX) -23%, Iovance Biotherapeutics (IOVA) -18%,&...
Lixte Biotechnology Holdings (LIXT) +21%.LightPath Technologies (LPTH) +16%.Reata Pharmaceuticals (RETA) +14% as FDA requested pre-NDA meeting for Omaveloxolone.Verona Pharma (VRNA) +10%.Cerecor (CERC) +6%.TAT Technologies (TATT) +5% on partnership with Lufthansa Technik Shenzhen ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning and prepare yourself for another busy day of trading! We’re kicking off our coverage today with a look at the biggest pre-market stock movers for Wednesday. Source: ventdusud / Shutterstock.com B...
ROCKVILLE, Md. and CHESTERBROOK, Pa., May 17, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases, today announced that members of its senior manage...
Cerecor (CERC): Q1 GAAP EPS of -$0.32 misses by $0.13.Revenue of $0.47M (-82.9% Y/Y) misses by $0.07M.Press Release For further details see: Cerecor EPS misses by $0.13, misses on revenue
Announced CERC-002 received Fast Track Designation from the U.S. Food and Drug Administration, following positive Phase 2 clinical trial for the treatment of patients hospitalized with COVID-19 ARDS Secured exclusive, world-wide rights to develop, manufacture and commercialize...
News, Short Squeeze, Breakout and More Instantly...
Topline results from planned Phase 2 trial of AVTX-009 in hidradenitis suppurativa expected in 2026 Cash on hand of approximately $110 million as of March 31, 2024 with expected cash runway into 2027 WAYNE, Pa. and ROCKVILLE, Md., May 13, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeut...
Appointments include industry veterans Aaron Kantoff, Jonathan Goldman, and Samantha Truex as Independent Directors Board of Director appointments in conjunction with Avalo’s recent acquisition of AVTX-009, an anti-IL-1β mAb, and up to $185 million private placement financ...
Acquired AVTX-009, Phase-2 ready anti-IL-1β mAb, in March 2024 Increased cash position with private placement financing in March 2024 providing up to $185 million, including initial upfront investment of $115.6 million Topline results from planned Phase 2 trial of AVTX-00...